Limits...
HIV Drug Therapy in the Americas 16-18 April 2015, Mexico City, Mexico.

- J Int AIDS Soc (2015)

View Article: PubMed Central - PubMed

ABSTRACT

Antiretroviral therapies have proved life-saving in HIV infection, dramatically reducing morbidity and mortality. With longer survival, morbidities and mortalities in HIV infection are increasingly similar to the morbidities and mortalities associated with ageing. In treated HIV infection, the risk of these morbidities and mortalities is linked to immune activation, inflammation and coagulation indices. And in persons with treated HIV infection, failure to restore circulating CD4 T cell numbers is associated with a greater risk of morbidities and mortalities as well as to heightened levels of inflammation and coagulation. The drivers of immune activation, inflammation and coagulation in treated HIV infection are incompletely defined and could be related to sustained low levels of viral replication in tissues, to translocation of microbial products across a damaged gut mucosa, to replication of co-pathogens such as cytomegalovirus, to increased levels of inflammatory lipids, or to homeostatic responses to lymphocytopenia that may drive expansion of CD8 T cell numbers. We present here models that link inflammation and coagulation to morbid outcomes as well as to the pathogenesis of CD4 T cell restoration failure and CD8 T cell expansion.

No MeSH data available.


CHIKV specific IgM detection in HIV (−) and HIV (+) individuals after onset of symptoms, Dominican Republic 2014.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401943&req=5

F0001_20134: CHIKV specific IgM detection in HIV (−) and HIV (+) individuals after onset of symptoms, Dominican Republic 2014.

Mentions: A total of 100 cases were tested. Women represented 73% (n=37), while men represented 27% (n=14). The immunological status in HIV positive was measured with the level of CD4+ T cells at the moment of onset of symptoms; 76.4% (n=39) having greater than 350 cells/µl, followed by 19.6% (n=10) with 101–350 cells/µl. HIV viral load was undetected in 74.5% (n=38) of the sample, and 11.7% (n=6) with a VL >50,000 copies/ml. CHIKV-IgM detection in HIV(+) was positive in 21.57% (n=11), and 30.61% in HIV(–). First positive IgM detection in HIV(–) was observed after one month of onset of symptoms; while in HIV(+) was 2w 1d (Figure 1 and Table 1).


HIV Drug Therapy in the Americas 16-18 April 2015, Mexico City, Mexico.

- J Int AIDS Soc (2015)

CHIKV specific IgM detection in HIV (−) and HIV (+) individuals after onset of symptoms, Dominican Republic 2014.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401943&req=5

F0001_20134: CHIKV specific IgM detection in HIV (−) and HIV (+) individuals after onset of symptoms, Dominican Republic 2014.
Mentions: A total of 100 cases were tested. Women represented 73% (n=37), while men represented 27% (n=14). The immunological status in HIV positive was measured with the level of CD4+ T cells at the moment of onset of symptoms; 76.4% (n=39) having greater than 350 cells/µl, followed by 19.6% (n=10) with 101–350 cells/µl. HIV viral load was undetected in 74.5% (n=38) of the sample, and 11.7% (n=6) with a VL >50,000 copies/ml. CHIKV-IgM detection in HIV(+) was positive in 21.57% (n=11), and 30.61% in HIV(–). First positive IgM detection in HIV(–) was observed after one month of onset of symptoms; while in HIV(+) was 2w 1d (Figure 1 and Table 1).

View Article: PubMed Central - PubMed

ABSTRACT

Antiretroviral therapies have proved life-saving in HIV infection, dramatically reducing morbidity and mortality. With longer survival, morbidities and mortalities in HIV infection are increasingly similar to the morbidities and mortalities associated with ageing. In treated HIV infection, the risk of these morbidities and mortalities is linked to immune activation, inflammation and coagulation indices. And in persons with treated HIV infection, failure to restore circulating CD4 T cell numbers is associated with a greater risk of morbidities and mortalities as well as to heightened levels of inflammation and coagulation. The drivers of immune activation, inflammation and coagulation in treated HIV infection are incompletely defined and could be related to sustained low levels of viral replication in tissues, to translocation of microbial products across a damaged gut mucosa, to replication of co-pathogens such as cytomegalovirus, to increased levels of inflammatory lipids, or to homeostatic responses to lymphocytopenia that may drive expansion of CD8 T cell numbers. We present here models that link inflammation and coagulation to morbid outcomes as well as to the pathogenesis of CD4 T cell restoration failure and CD8 T cell expansion.

No MeSH data available.